RE:TBP solution to opioid crisis As Bloomberg reported, “The stigma surrounding the $7.2 billion marijuana industry is evaporating as Americans grow increasingly comfortable with the concept, more states allow medical and recreational use, and pot businesses start generating healthy profits.”[17]
And investors are taking notice.
Marijuana stocks are booming as investors race to take part in the “Green Rush”. But you have to know how to find those companies before they explode, separating the blockbusters from the duds. Do your research and find your entry point where you are comfortable.
Here are Three Stocks I am Paying Special Attention to Right Now
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries that are engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
Cronos Group Inc. (CRON) is a Toronto-based cultivator of medical marijuana, and was Nasdaq’s first pot stock. In addition to Canada, Cronos serves an international market. It ships its products to Germany, is building a facility in Israel and has a license through a joint venture in Australia. While it does not have a presence in the United States due to the uncertainty in regulations, as of the fiscal year ending March 31, 2018 the company generated $2.2 million in revenue.
Tilray Inc. (NASDAQ: TLRY) has rapidly become the most valuable marijuana company in the world. The company’s $13.6 billion market cap, after all, is substantially higher than those of either Canopy Growth Corporation (NYSE:CGC) or Aurora Cannabis (TSX:ACB) — Canada’s second and third most valuable cannabis-oriented businesses, respectively.
Tilray cultivates a wide range of strains to meet patient needs including indicas, sativas, hybrids, and CBD-rich varieties. They take a scientific approach to product development with a product line focused on active ingredients and standardized, well-defined preparations. Their formulations and delivery formats are intended to allow for consistent and measured dosing.
In October 2018, the company announced a massive convertible senior note offering of $450 million. This will greatly increase their cash flow for acquisitions of smaller players, keeping competition low and prices high for dried flower.